Changzhou Qianhong Biopharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021
April 19, 2021 at 05:30 am EDT
Share
Changzhou Qianhong Biopharma CO.,LTD announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 391.207 million compared to CNY 145.850 million a year ago. Operating income was CNY 68.509 million compared to operating loss of CNY 20.316 million a year ago. Net income was CNY 54.359 million compared to net loss of CNY 25.354 million a year ago. Basic earnings per share from continuing operations was CNY 0.04 compared to basic loss per share from continuing operations of CNY 0.02 a year ago.
Changzhou Qianhong Biopharma CO., LTD is a China-based company, principally engaged in the research and development, production and distribution of freeze-drying powder, freeze-drying powder injections, small volume injections, tablets, hard capsules, granules and bulk drugs, among others. The Company mainly provides liquaemin sodium raw materials and preparations, applied to prevent and treat thromboembolism desease; kallidinogen preparations, applied in the treatment of micro-circulation disorder disease, asparaginase bulk drugs and preparations, applied in the treatment of acute lymphoblastic leukemia, as well as compound digestive enzyme capsules II. The Company distributes its products within domestic market and to overseas markets.
CHANGZHOU QIANHONG BIOPHARMA CO.,LTD 
